Ankit J Kansagra, Noelle V Frey, Merav Bar, Theodore W Laetsch, Paul A Carpenter, Bipin N Savani, Helen E Heslop, Catherine M Bollard, Krishna V Komanduri, Dennis A Gastineau, Christian Chabannon, Miguel A Perales, Michael Hudecek, Mahmoud Aljurf, Leslie Andritsos, John A Barrett, Veronika Bachanova, Chiara Bonini, Armin Ghobadi, Saar I Gill, Joshua Hill, Saad Kenderian, Partow Kebriaei, Arnon Nagler, David Maloney, Hien D Liu, Nirali N Shah, Mohamed A Kharfan-Dabaja, Elizabeth J Shpall, Ghulam J Mufti, Laura Johnston, Elad Jacoby, Ali Bazarbachi, John F DiPersio, Steven Z Pavletic, David L Porter, Stephan A Grupp, Michel Sadelain, Mark R Litzow, Mohamad Mohty, Shahrukh K Hashmi
On August 30, 2017 the US Food and Drug Administration approved tisagenlecleucel (Kymriah; Novartis, Basel, Switzerland), a synthetic bioimmune product of anti-CD19 chimeric antigen receptor T cells (CAR-T), for the treatment of children and young adults with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL). With this new era of personalized cancer immunotherapy, multiple challenges are present, ranging from implementation of a CAR-T program to safe delivery of the drug, long-term toxicity monitoring, and disease assessments...
March 2019: Biology of Blood and Marrow Transplantation